Latest Shareholder Meetings News

Vault Minerals has secured a key regulatory waiver from the ACCC for its merger with Genesis Minerals, removing a major obstacle and keeping the deal on track for shareholder approval later this year.

Heartland has cleared a major hurdle in its $620 million acquisition of TSB, with Toi Foundation trustees approving the sale. The merger aims to create a stronger regional challenger bank, pending shareholder and regulatory green lights.

Winton Land reported a 120% rise in net profit to $22.7 million in FY26, driven by increased residential settlements and full-year trading at its hospitality venues, despite economic headwinds and leadership changes.

Lithium Universe Limited has secured $848,452 through the first tranche of a share placement, setting the stage for advancing its Brownsville lithium refinery and innovative recycling technologies.

Hamelin Gold has issued nearly 50 million shares in the first tranche of its $8 million placement, targeting exploration at key Western Australian projects. The second tranche, including director participation, awaits shareholder approval.

Chorus reported solid FY26 results with revenue growth driven by fibre expansion and disciplined cost management, while accelerating copper network retirement and launching new digital infrastructure services.

BCAL Diagnostics has updated investors on its $10 million convertible note facility, revealing $7.6 million drawn to date with further funding contingent on upcoming shareholder approval.

Greenvale Energy is pushing forward with its strategic acquisition of uranium rights at Pine Creek, aiming to create a 2,500km² contiguous exploration footprint alongside Douglas River. A critical shareholder vote is set for August 24 to approve the deal.

General Capital’s 2026 Annual Shareholders Meeting saw a notable board shake-up as investors declined to re-elect Brent Douglas King, while approving a near 10% hike in directors' remuneration.

Fisher & Paykel Healthcare has raised its full-year net profit guidance for FY2027, buoyed by robust first-half sales and a $23 million US tariff refund. The medical devices maker forecasts up to 24% profit growth in H1, driven by hospital product demand and operational efficiencies.

Pacific Edge’s draft Medicare Local Coverage Determination for its Cxbladder bladder cancer tests marks a pivotal step toward unlocking a $10.2 billion global market. Despite FY26 setbacks, the company is poised for growth with improved reimbursement prospects and strategic cost management.

CZR Resources Ltd (ASX:CZR) has launched an all-scrip off-market takeover bid for Zuleika Gold Limited (ASX:ZAG), offering 0.1742 CZR shares per Zuleika share, valuing Zuleika at approximately $44.8 million and representing a premium of over 40% to recent prices.